Circulating tumour cells for the prediction of the response to radiation therapy in prostate cancer.
1/5 보강
Circulating tumour cells (CTCs) have emerged as a promising biomarker for assessing prognosis and predicting therapeutic efficacy in various cancers, including metastatic prostate cancer.
APA
Landry C, Klusa D, et al. (2025). Circulating tumour cells for the prediction of the response to radiation therapy in prostate cancer.. The British journal of radiology, 98(1175), 1899-1911. https://doi.org/10.1093/bjr/tqaf224
MLA
Landry C, et al.. "Circulating tumour cells for the prediction of the response to radiation therapy in prostate cancer.." The British journal of radiology, vol. 98, no. 1175, 2025, pp. 1899-1911.
PMID
40971628 ↗
Abstract 한글 요약
Circulating tumour cells (CTCs) have emerged as a promising biomarker for assessing prognosis and predicting therapeutic efficacy in various cancers, including metastatic prostate cancer. However, predicting patient response to treatment, including radiation therapy (RT), remains a significant clinical challenge. This review explores the value of CTCs as prognostic markers in RT for prostate cancer, discussing their detection methods, biological significance, clinical relevance, and future implications.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.